We found that telaglenastat used in combination with imatinib in leukemic cell line as well as in primary CD34 + cells from CML patients attenuated the stroma-mediated protection from imatinib (Fig. 7). Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.